Project

Back to overview

Intelligent synthetic nanosize organelles as novel therapy for cancer

English title Intelligent synthetic nanosize organelles as novel therapy for cancer
Applicant Hunziker Patrick
Number 126078
Funding scheme NRP 62 Smart Materials
Research institution Klinik für Intensivmedizin Universitätsspital Basel
Institution of higher education University of Basel - BS
Main discipline Material Sciences
Start/End 01.02.2010 - 31.01.2015
Approved amount 860'011.00
Show all

Keywords (5)

Nanomedicine; Medicine; Cancer; Intelligent Materials; Nanoscience

Lay Summary (German)

Lead
Dieses Projekt entwickelt, und testet neuartige, reaktive, polymerbasierte Nanomaterialien, welche zur Behandlung von Krebs geeignet sind.
Lay summary
Das Projekt basiert auf unseren Vorarbeiten, welche zu synthetischen Organellen geführt haben. Diese Nano-Objekte haben die Fähigkeit, in der Blutbahn zu zirkulieren, Krebszellen aufzuspüren und an sie zu binden. Nach "Anschalten" der Objekte mittels Licht kann die angepeilte Krebszelle gezielt vernichtet werden. Ein besonderes Augenmerk wurde darauf gerichtet, dass diese Objekte ein sehr geringes Potential für Nebenwirkungen haben.
Direct link to Lay Summary Last update: 23.06.2015

Lay Summary (English)

Lead
Complexity of life and of disease processes is clearly discernible even in the nanoscale. Can these insights be used to inspire a new class of novel, synthetic nano-size objects with complex functionality (synthetic organelles) useful for the therapy of severe diseases like cancer?
Lay summary

Background
The nanosciences have shown that fundamental biological events are based on processes in the nanoscale, in health as well as in disease. In comparison to the complex, functional natural nano-objects of the living cell, today’s technical nanoparticles are very simple in structure and function.

Aim
The goal of this project is, therefore, to design and synthesize artificial nanosize objects of increasing complexity and functionality suited as novel medical applications (therapies for cancer), and to test such synthetic organelles in cell culture and cancer models in the intact organism. Despite their small size (nanometer scale), first prototypes of such synthetic organelles are already showing the capability to deploy switchable functionality of biological relevance. To achieve the goals of the project, polymer chemistry, biochemistry, analytic
and biomedical methods are used in concert.

Significance
Scientifically, the design and the production of functional and reversibly activatable synthetic nanoscale objects is a challenge: how much complexity can be implemented at such a small scale? Can the expected advantages of such objects, namely selectivity for the diseased organs, effectiveness enhancement together with side effect reduction, and switchability, be confirmed experimentally? What is the behaviour of such objects in the intact organism?

Application
The primary goal of the project is the development of intelligent nanoscale organelles for cancer therapy. Beyond this application, there exists the potential for nanoscale objects with complex, reversible functionality to become a future platform technology. Therefore, it is expected to gain, beyond the medical application, important insights into the potential, the challenges, necessary synthesis methods and optimal applications of such complex nanosystems.


Direct link to Lay Summary Last update: 23.06.2015

Responsible applicant and co-applicants

Employees

Publications

Publication
Towards Personalized and Curative Medicine
Hunziker P (2015), Towards Personalized and Curative Medicine, in Bengt Fadeel (ed.), CRC press, London, 523-532.
Comprehensive targeting: the avenue to a personalized, highly effective, innocuous, and cost-effective medicine of the future.
Hunziker P (2013), Comprehensive targeting: the avenue to a personalized, highly effective, innocuous, and cost-effective medicine of the future., in European Journal of Nanomedicine , 5, 3-4.
Intelligent nanomaterials for medicine: Carrier platforms and targeting strategies in the context of clinical application
R Lehner X Wang S Marsch P Hunziker (2013), Intelligent nanomaterials for medicine: Carrier platforms and targeting strategies in the context of clinical application, in Nanomedicine: Nanotechnology, Biology and Medicine, 9, 742-757.
Plasmid linearization changes shape and efficiency of transfection complexes
R Lehner X Wang P Hunziker (2013), Plasmid linearization changes shape and efficiency of transfection complexes, in European Journal of Nanomedicine , 5, 205-212.
“Widespread orphan diseases”–A call for research, development strategies, and regulatory pathways for fre-quent diseases with multiple molecularly defined subgroups
Hunziker (2012), “Widespread orphan diseases”–A call for research, development strategies, and regulatory pathways for fre-quent diseases with multiple molecularly defined subgroups, in Eur J Nanomedicine, 4, 55-56.
Designing switchable nanosystems for medical application
R Lehner X Wang M Wolf P Hunziker (2012), Designing switchable nanosystems for medical application, in J Controlled Release, 161(2), 307-316.
Designing switchable nanosystems for medical application
Lehner R, Wang XY, Wolf M, Hunziker P (2012), Designing switchable nanosystems for medical application, in JOURNAL OF CONTROLLED RELEASE, 161(2), 307-316.
Nanomedicine - shaping the medicine of the future
Hunziker P (2012), Nanomedicine - shaping the medicine of the future, 22(1), 22(1).
Nanomedicine - shaping the medicine of the future
Hunziker Patrick (2012), Nanomedicine - shaping the medicine of the future, in ZEITSCHRIFT FUR MEDIZINISCHE PHYSIK, 22(1), 1-3.
Polydimethylsiloxane embedded mouse aorta ex vivo perfusion model: proof-of-concept study focusing on atherosclerosis
Wang Xueya, Wolf Marc P., Keel Rahel Banziger, Lehner Roman, Hunziker Patrick R. (2012), Polydimethylsiloxane embedded mouse aorta ex vivo perfusion model: proof-of-concept study focusing on atherosclerosis, in JOURNAL OF BIOMEDICAL OPTICS, 17(7), 0760061-0760068.
Why not just switch on the light?: light and its versatile applications in the field of nanomedicine
R Lehner P Hunziker (2012), Why not just switch on the light?: light and its versatile applications in the field of nanomedicine, in European Journal of Nanomedicine, 4, 73-80.
Reconstruction of Large, Irregularly Sampled Multidimensional Images. A Tensor-Based Approach
Morozov OV, Unser M, Hunziker P (2011), Reconstruction of Large, Irregularly Sampled Multidimensional Images. A Tensor-Based Approach, in IEEE TRANSACTIONS ON MEDICAL IMAGING, 30(2), 366-374.
Towards Targeted Drug Delivery by Covalent Ligand-Modified Polymeric Nanocontainers
Egli S, Fischer B, Hartmann S, Hunziker P, Meier W, Rigler P (2010), Towards Targeted Drug Delivery by Covalent Ligand-Modified Polymeric Nanocontainers, in MODERN TRENDS IN POLYMER SCIENCE-EPF 09, 296, 278-285.

Collaboration

Group / person Country
Types of collaboration
ETH Zürich Switzerland (Europe)
- in-depth/constructive exchanges on approaches, methods or results
- Publication
- Exchange of personnel
Uni Bern Switzerland (Europe)
- in-depth/constructive exchanges on approaches, methods or results
EPF Lausanne Switzerland (Europe)
- in-depth/constructive exchanges on approaches, methods or results
- Publication
- Exchange of personnel
Uni Freiburg i.Br Germany (Europe)
- in-depth/constructive exchanges on approaches, methods or results

Scientific events

Active participation

Title Type of contribution Title of article or contribution Date Place Persons involved
New York Academy of Sciences Talk given at a conference Nanomedicines: Addressing the Scientific and Regulatory Gap 21.11.2013 New York, United States of America Hunziker Patrick;
Vulnerable Plaque Meeting Talk given at a conference Targeting the vulnerable plaque by nanocarriers 23.06.2012 Athen, Greece Hunziker Patrick;
EuroNanoBio 2012 Talk given at a conference Keynote Lecture 16.06.2012 Milano, Italy Hunziker Patrick;
Nanomedizin Symposium Pharmazentrum Talk given at a conference Nanomedicine 07.03.2012 Basel, Switzerland Hunziker Patrick;
Jahrestagung Schweizer Pharmakologen Talk given at a conference ... 23.11.2011 Zurich, Switzerland Hunziker Patrick;
"Nanoscience et Medicine" Institut Servier Talk given at a conference Nanomedical Synthetic Organelles 17.11.2011 Paris, France Hunziker Patrick;
Conference American Association of Pharmaceutical Scientists Talk given at a conference The European landscape in nanomedicine 23.10.2011 Washington, United States of America Hunziker Patrick;
European Technology Platform Nanomedicine Talk given at a conference Stride Towards Bringing Nanomedicine from Bench to Bed 21.10.2011 Barcelona, Spain Hunziker Patrick;
Mona Lisa Kickoff Meeting Talk given at a conference Nanomedicine 06.10.2011 Udine , Italy Hunziker Patrick;
EuCOR Meeting Personalisierte Medizin Talk given at a conference With Nanomedicine towards Personalized Medicine – Now and Future 28.09.2011 Freiburg i.Br, Germany Hunziker Patrick;
Summer School Nanomedicine Wittenberg Talk given at a conference Applying nanoscience and computational science to create an effective, safe, curative and affordable medicine of the future 19.06.2011 Wittenberg, Germany Hunziker Patrick;
NanoConvention Talk given at a conference Nanomedicine - a key ingredient of the medicine of the future 18.05.2011 Zurich, Switzerland Hunziker Patrick;
Nanomedicine for Cancer, European SFRP Pediatrics Conference Talk given at a conference Intelligent synthetic nanosize organelles as novel therapy for cancer 11.05.2011 marseille, France Hunziker Patrick;
Seminar Translational Medicine Uni Basel Talk given at a conference Translational Nanosciences, a Way to Personalised Medicine 05.05.2011 Basel, Switzerland Hunziker Patrick;
Annual Meeting Schweiz.Ges.Phrmakologie und Toxikologie Talk given at a conference Nanomedizin – Stark, Sanft, Nachhaltig 27.04.2011 Zürich, Switzerland Hunziker Patrick;
NanoCAN Meeting personalized medicine Talk given at a conference Personalized Cancer Medicine 14.04.2011 Odense, DE, Germany Hunziker Patrick;
Seminar Nanomedizin EMPA Individual talk Medikamente mit Pfadfinderfunktion 09.04.2011 St.Gallen, Switzerland Hunziker Patrick;
Kickoff meeting NFP64 Talk given at a conference Keynote Lecture 03.03.2011 Nottwil, Switzerland Hunziker Patrick;
NanoImpactNet Talk given at a conference Opening the scene - Creating bridges between nanomedicine and NanoImpactNet research 14.02.2011 Lausanne, Switzerland Hunziker Patrick;
Biotech Net Olten Tagung Talk given at a conference Drug delivery systems reduce undesirable side effects and help to intensify the effect of the medicine 24.11.2010 Olten, Switzerland Hunziker Patrick;
Translational Meet&Match Symposium Freiburg i.Br Talk given at a conference Cell targeting by a generic specifically directed polymer nanocontainer 05.11.2010 Freiburg i.Br., Germany Hunziker Patrick;
Nanotech Italia - Annual Meeting Talk given at a conference Nanotechnology - why and how it will shape the medicine of the future 20.10.2010 Venedig, Italy Hunziker Patrick;
Nanomedicine Symposium Semmelweis Universität Talk given at a conference Nanomedicine for personal therapy 15.10.2010 Budapest, Hungary Hunziker Patrick;
Annual Meeting, European Technology Platform Nanomedicine Talk given at a conference Clinical Needs related to Nanomedicine 14.10.2010 Milano, Italy Hunziker Patrick;
Schweiz.Urologenkongress Talk given at a conference Nanomedicine for personal therapy 02.09.2010 Lausanne, Switzerland Hunziker Patrick;
Symposium Nanomedicine Erlangen Individual talk Nanomedicine for personal therapy 02.09.2010 Erlangen, Switzerland Hunziker Patrick;
Nanobio Europe Talk given at a conference Keynote Lecture 25.08.2010 Zurich, Switzerland Hunziker Patrick;


Self-organised

Title Date Place
European Conference for Clinical Nanomedicine 23.06.2013 Basel, Switzerland
European Summit for Clinical Nanomedicine 14.05.2012 Basel, Switzerland
European Conference for Clinical Nanomedicine 07.05.2012 Basel, Switzerland
European Conference for Clinical Nanomedicine 23.05.2011 Basel, Switzerland
European Conference for Clinical Nanomedicine 10.05.2010 Basel, Switzerland

Communication with the public

Communication Title Media Place Year
Media relations: print media, online media «Nanomedizin ist ein zentrales Standbein der Medizin der Zukunft» inet news German-speaking Switzerland 2014
Talks/events/exhibitions Nanomedizin: Der Weg zu einer effektiveren, personalisierten, kosteneffizienten Medizin German-speaking Switzerland 2012
Talks/events/exhibitions Vortrag Naturforschende Gesellschaft Basel German-speaking Switzerland 2012
Media relations: radio, television Interview 10 vor 10 Schweizer Fernsehen German-speaking Switzerland 2011
Media relations: print media, online media Nanomedizin Basellandschschaftliche Zeitung German-speaking Switzerland 2011
Talks/events/exhibitions Vortrag Naturforschende Gesellschaft Winterthur German-speaking Switzerland 2011
Media relations: print media, online media mit superzwergen den krebs besiegen medcom24 German-speaking Switzerland 2010
Talks/events/exhibitions Nanotechnologie für Mensch und Gesundheit International 2010

Use-inspired outputs


Start-ups

Name Year
Spheroidals - is currently being established 2015

Associated projects

Number Title Start Funding scheme
135615 Cellular crosstalk by secreted proprotein convertases and by Nodal 01.08.2011 Project funding (Div. I-III)

Abstract

The goals of the project are to develop, and to explore the medical utility of a novel class of intelligent synthetic nanoscale materials built from polymers, that are able to react upon external stimuli, to trigger or perform biochemical reactions, and to perform this functionality on the level of a target cell and within the organism and to assess the potential of such materials in cancer in cell culture and small animal models.By combining medical synthesis, physical characterisation, and biomedical evaluation, we have created a number of novel intelligent materials that proved to be highly promizing for future cancer therapies: They are non-toxic, are able to target cancer tissues in several human cancer models selectively, and can be "switched on" at the target to exert strong therapeutic effects while sparing healthy cells and tissues.
-